Panmure Gordon reaffirmed their buy rating on shares of ImmuPharma PLC (LON:IMM) in a research report sent to investors on Wednesday. The firm currently has a GBX 100 ($1.33) price objective on the stock.

Other research analysts have also issued reports about the company. Northland Securities reaffirmed a corporate rating on shares of ImmuPharma PLC in a research report on Monday, June 20th. Northland Capital Partners began coverage on ImmuPharma PLC in a report on Wednesday, July 20th. They set a buy rating and a GBX 171 ($2.28) price target for the company.

Shares of ImmuPharma PLC (LON:IMM) opened at 39.00 on Wednesday. The company’s 50-day moving average price is GBX 37.53 and its 200 day moving average price is GBX 32.76. The company’s market cap is GBX 47.49 million. ImmuPharma PLC has a 12-month low of GBX 19.10 and a 12-month high of GBX 48.88.

About ImmuPharma PLC

ImmuPharma plc (ImmuPharma) is a United Kingdom-based is a drug discovery and development company. Its research operations are in France. The Company is engaged in the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions, such as autoimmune diseases. ImmuPharma is engaged in developing drug candidates for five different medical conditions.

Receive News & Ratings for ImmuPharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.